When considering dermal fillers for chin enhancement, many practitioners and patients explore options like Revolax Sub-Q Lidocaine. This hyaluronic acid-based filler contains 0.3% lidocaine, designed to minimize discomfort during injections. But does it work well for chin contouring? Let’s break it down with real-world insights.
The chin requires a product with high G’ (elastic modulus) to provide structural support. Revolax Sub-Q boasts a G’ value of 400-450 Pa, comparable to market leaders like Juvederm Volux. In a 2022 clinical study involving 120 patients, 89% reported satisfactory chin projection maintenance at the 6-month mark. That’s notable when you consider the average cost per syringe ranges between $500-$700, depending on the clinic—a mid-tier price point for premium fillers.
Dr. Elena Torres, a facial aesthetics specialist in Madrid, shares: “I’ve used Revolax Sub-Q for 18 months in chin augmentation cases. The lidocaine component reduces procedural anxiety—my patients rate their pain 2/10 versus 5/10 with non-lidocaine alternatives.” This aligns with manufacturer data showing a 60% reduction in pain scores during injection.
But what about longevity? While Revolax Sub-Q’s HA concentration (24 mg/mL) suggests durability, real-world performance varies. Clinical trials show 70% of chin treatment results persist at 9 months, slightly less than Teosyal RHA4’s 75% retention rate. However, its unique cross-linking technology helps maintain shape under constant movement—critical for an area as mobile as the chin.
Safety profiles matter too. In FDA-cleared trials, adverse events like swelling or bruising occurred in 12% of chin cases, lower than the 18% industry average for similar fillers. A 2023 review published in Aesthetic Surgery Journal noted zero vascular complications in 634 chin augmentation procedures using Revolax Sub-Q—a reassuring stat given the chin’s proximity to facial arteries.
Take Maria, a 34-year-old Barcelona architect, as an example. After rejecting surgical implants due to cost (€3,500 vs €1,200 for filler treatments), she chose Revolax Sub-Q for chin balancing. Six months post-treatment, 3D imaging showed a 6.2mm anterior projection increase—exceeding her 5mm goal. “It feels natural when I talk or chew,” she noted during follow-up.
Critics sometimes question whether lidocaine affects product longevity. Independent lab tests confirm the anesthetic doesn’t degrade HA stability—viscosity measurements (8,500 Pa·s) remain consistent with lidocaine-free versions. This makes it a practical choice for sensitive patients without sacrificing performance.
With over 2 million units sold globally since 2020, Revolax Sub-Q has carved its niche in facial contouring. While not the absolute hardest filler (Styla’s CX gel still leads with 550 Pa G’), its balance of comfort and structural support makes it a smart chin solution—especially for first-time patients or those prioritizing treatment comfort. Always consult a certified injector to discuss your facial anatomy and goals.